The estimated Net Worth of Raymond M Jordt is at least $80.4 mil dollars as of 1 January 2024. Raymond Jordt owns over 9,375 units of Altimmune Inc stock worth over $80,354 and over the last 2 years Raymond sold ALT stock worth over $0.
Raymond has made over 1 trades of the Altimmune Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Raymond exercised 9,375 units of ALT stock worth $67,219 on 1 January 2024.
The largest trade Raymond's ever made was exercising 9,375 units of Altimmune Inc stock on 1 January 2024 worth over $67,219. On average, Raymond trades about 1,563 units every 0 days since 2023. As of 1 January 2024 Raymond still owns at least 11,207 units of Altimmune Inc stock.
You can see the complete history of Raymond Jordt stock trades at the bottom of the page.
Raymond's mailing address filed with the SEC is C/O ALTIMMUNE, INC., 910 CLOPPER ROAD,, SUITE 201S, GAITHERSBURG, MD, 20878.
Over the last 7 years, insiders at Altimmune Inc have traded over $2,557,810 worth of Altimmune Inc stock and bought 3,362,060 units worth $23,898,779 . The most active insiders traders include Bioventures Ltd Novartis Ag..., Healthcare Capital Partners..., eMitchel Sayare. On average, Altimmune Inc executives and independent directors trade stock every 35 days with the average trade being worth of $432,889. The most recent stock trade was executed by David Drutz on 19 August 2024, trading 41,750 units of ALT stock currently worth $106,463.
altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current
Altimmune Inc executives and other stock owners filed with the SEC include: